Activation of the PI3K-AKT-mTOR pathway can contribute to therapy resistance by directly promoting tumor cell proliferation and survival, as well as the upregulation of PD-L1 cell surface expression, thereby inhibiting the function of local effector T cells [94]. This evidence concerns the gene CD274 and neoplasm.